請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15705完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林中梧 | |
| dc.contributor.author | Ting-Chu Lin | en |
| dc.contributor.author | 林庭竹 | zh_TW |
| dc.date.accessioned | 2021-06-07T17:50:26Z | - |
| dc.date.copyright | 2013-03-04 | |
| dc.date.issued | 2012 | |
| dc.date.submitted | 2012-12-23 | |
| dc.identifier.citation | References
1. Lin CW, Lee WH, Chang CL, Yang JY, Hsu SM: Restricted killer cell immunoglobulin-like receptor repertoire without T-cell receptor gamma rearrangement supports a true natural killer-cell lineage in a subset of sinonasal lymphomas. Am J Pathol 2001;159:1671-1679. 2. Lin CW, Chen YH, Chuang YC, Liu TY, Hsu SM: CD94 transcripts imply a better prognosis in nasal-type extranodal NK/T-cell lymphoma. Blood 2003;102:2623-2631. 3. Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, Kim TY, Kim CW, Heo DS, Bang YJ, Chang KH, Kim NK: Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005;106:3785-3790. 4. Lin TC, Chen SU, Chen FC, Chang YC, Lin CW: Intramucosal variant of nasal NK/T-cell lymphoma has a better survival than invasive variant does: implication on loss of ETS-1 and T-bet with invasion. Histopathology 2012;60:287-295. 5. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH: A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000;100:655-669 6. Afkarian M, Sedy JR, Yang J, Jacobson NG, Cereb N, Yang SY, Murphy TL, Murphy KM: T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol 2002;3:549-557. 7. Steiner DF, Thomas MF, Hu JK, Yang Z, Babiarz JE, Allen CD, Matloubian M, Blelloch R, Ansel KM: MicroRNA-29 regulates T-box transcription factors and interferon-γ production in helper T cells. Immunity 2011;35:169-181. 8. Ma F, Xu S, Liu X, Zhang Q, Xu X, Liu M, Hua M, Li N, Yao H, Cao X: The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ. Nat Immunol 2011;12:861-869. 9. Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, John B, Enright AJ, Marks D, Sander C, Tuschl T: Identification of virus-encoded microRNAs. Science 2004;304:734-736. 10. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ: MiRBase: tools for microRNA genomics. Nucleic Acid Res 2008;36(Database Issue):D154-158. 11. Edwards RH, Marquitz AR, Raab-Traub N: Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. J Virol 2008;82:9094-9106. 12. Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, Raab-Traub N, Cullen BR: Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2006;2:e23. 13. Qiu J, Cosmopoulos K, Pegtel M, Hopmans E, Murray P, Middeldorp J, Shapiro M, Thorley-Lawson DA: A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia. PLoS Pathog 2011;7:e1002193. 14. Kwong YL: Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005;19:2186-2194. 15. Liang X, Graham DK: Natural killer cell neoplasms. Cancer 2008;112:1425-1436. 16. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005;33:e179. 17. Liu TY, Chen SU, Kuo SH, Cheng AL, Lin CW: E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: possible correlation with stage and treatment response. Modern Pathol 2010;23:1507-1517. 18. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R: Fast and effective prediction of microRNA/target duplexes. RNA 2004;10:1507-1517. 19. Jenner RG, Townsend MJ, Jackson I, Sun K, Bouwman RD, Young RA, Glimcher LH, Lord GM: The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes. Proc Natl Acad Sci U S A 2009;106:17876-17881. 20. Muller PA, Vousden KH, Norman JC: p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011;192:209-218. 21. Lu C, El-Deiry WS: Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009;14:597-606. 22. Cheung KJ, Horsman DE, Gascoyne RD: The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol 2009;146:257-269 . 23. Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, Greiner TC, McDonnell TJ, Young KH: Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012;119:3668-3683. 24. Quintanilla-Martinez L, Kremer M, Keller G, Nathrath M, Gamboa-Dominguez A, Meneses A, Luna-Contreras L, Cabras A, Hoefler H, Mohar A, Fend F: p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. Am J Pathol 2001;159:2095-2105. 25. Wilson V, Conlon FL: The T-box family. Genome Biol 2002;3:3008.1-3008.7. 26. Naiche LA, Harrelson Z, Kelly RG, Papaioannou VE. T-box genes in vertebrate development. Annu Rev Genet 2005;39:219-239. 27. Chinen H, Matsuoka K, Sato T, Kamada N, Okamoto S, Hisamatsu T, Kobayashi T, Hasegawa H, Sugita A, Kinjo F, Fujita J, Hibi T: Lamina propria c-kit+ immune precursors reside in human adult intestine and differentiate into natural killer cells. Gastroenterology 2007;133:559-573. 28. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK, Caligiuri MA: Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006;203:1033-1043. 29. Jenner RG, Townsend MJ, Jackson I, Sun K, Bouwman RD, Young RA, Glimcher LH, Lord GM: The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes. Proc Natl Acad Sci U S A 2009;106:17876-17881. 30. Miller SA, Weinmann AS: Common themes emerge in the transcriptional control of T helper and developmental cell fate decisions regulated by the T-box, GATA and ROR families. Immunology 2009;126:306-315. 31. Lo AK, To KF, Lo KW, Lung RW, Hui JW, Liao G, Hayward SD: Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U S A 2007;104:16164-16169. 32. Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O: Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 2009;5:376-385. 33. Choy EY, Siu KL, Kok KH, Lung RW, Tsang CM, To KF, Kwong DL, Tsao SW, Jin DY: An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med 2008;205:2551-2560. 34. Xia T, O'Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB, Ramos JC, Luz E, Pedroso C, Manrique M, Toomey NL, Brites C, Dittmer DP, Harrington WJ Jr: EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res 2008;68:1436-1442. 35. Barth S, Pfuhl T, Mamiani A, Ehses C, Roemer K, Kremmer E, Jaker C, Hock J, Meister G, Grasser FA: Epstein-Barr virus-encoded microRNA miR-BART2 downregulates the viral DNA polymerase BALF5. Nucleic Acids Res 2008;36:666-675. 36. Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, Chau SL, Chan AW, Ng EK, Lo KW, To KF: Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 2009;11:1174- 1184. 37. Amoroso R, Fitzsimmons L, Thomas WA, Kelly GL, Rowe M, Bell AI: Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel insights into their regulation. J Virol 2011;85:996-1010. 38. Vereide D, Sugden B: Insights into the evolution of lymphomas induced by Epstein-Barr virus. Adv Cancer Res. 2010;108:1-19. 39. Riley KJ, Rabinowitz GS, Yario TA, Luna JM, Darnell RB, Steitz JA: EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency. EMBO J 2012;31:2207-2221. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15705 | - |
| dc.description.abstract | 目的：
NK/T細胞鼻淋巴癌源自於鼻黏膜，會透過局部的侵入擴散到相鄰的組織，或是遠端轉移到區域性淋巴結。本研究目的主要探討NK/T細胞鼻淋巴癌一旦具侵入性後對預後的影響，以及淋巴癌中細胞毒殺標誌表現與侵入的關聯。 方法與結果： 此研究選擇了64位NK/T細胞鼻淋巴癌病人，利用組織病理學方法去評估侵入之程度及組織免疫染色去看細胞毒殺細胞的標誌的表現，包含了看：ETS-1，T細胞中的T-bet，信息傳遞及活化轉錄因子STAT-1，CD56，granzyme B。其中有17位病人被歸類為無侵入性的第一期（又稱為Ia 或是黏膜型），有21位病人被歸類為侵入性的第一期（又稱為Ib），16位病人被歸類為第二期，10位病人被歸類為第三/四期。第Ia期的病人較Ib期及二、三/四期的病人五年內有較好的存活率（分別是85％，38％，33％，20％）。研究結果發現在第Ia期的病人中ETS-1的表現為24％（4/17），而第Ib及二、三/四期的病人ETS-1的表現為65％（28/43）；而T-bet在Ia期病人表現為29％（5/17），在Ib及二、三/四期病人表現為67％（30/45）。 結論： NK/T細胞鼻淋巴癌為典型的侵襲性淋巴癌，但是黏膜型的侵襲性較低。由實驗中發現，ETS-1及T-bet表現量的減少也與侵襲性低有相關，之後我們也會做其他相關的研究來進一步證實。 | zh_TW |
| dc.description.abstract | Aims: Nasal NK/T-cell lymphoma (NNKTCL) arises from the nasal mucosa, and spreads to adjacent tissues via local invasion or to regional lymph nodes and distant sites via metastasis. We studied the impact of invasion on the prognosis of NNKTCL, and correlated invasion with the expression of cytotoxic markers of lymphoma cells.
Methods and Results: Histopathologic evaluations of invasion and immunostains for cytotoxic markers, including EST-1, T-bet, STAT-1, CD56, and granzyme B, were performed in 64 NNKTCLs. There were 17 stage-I cases without invasion (stage Ia or intramucosal), 21 stage-I cases with invasion (stage Ib), 16 stage-II cases, and 10 stage-III/IV cases. Stage-Ia NNKTCLs had a better 5-year overall survival rate than that of stage-Ib, II, or III/IV NNKTCLs (85%, 38%, 33%, and 20%, respectively, p<0.001 by logrank test). Loss of ETS-1 was found in 24% (4/17) stage-Ia NNKTCLs and in 65% (28/43) stage-Ib/II/III/IV NNKTCLs (p=0.04, Fischer’s test); loss of T-bet was found in 29% (5/17) stage-Ia NNKTCLs and in 67% (30/45) stage-Ib/II/III/IV NNKTCLs (p=0.02, Fischer’s test). Conclusions: NNKTCL is classically an aggressive lymphoma, but the intramucosal variant is less aggressive. Loss of ETS-1 or T-bet correlated weakly with invasion, a finding that requires further confirmation. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-07T17:50:26Z (GMT). No. of bitstreams: 1 ntu-101-R97444003-1.pdf: 2142976 bytes, checksum: 6feec33232139a875b991252a28d7945 (MD5) Previous issue date: 2012 | en |
| dc.description.tableofcontents | Contents
口試委員會審定書……………….………………………………i PART 1. An intramucosal or non-invasive variant of nasal NK-cell lymphoma……....................................1 中文摘要……………………….................…........2 Abstract.............................................3 Introduction.........................................7 Materials and Methods................................9 Results.............................................12 Discussion..........................................16 References..........................................20 Table...............................................25 Figure..............................................28 PART 2. The EBV-encoded miR-BART20-5p inhibits T-bet with secondary suppression of p53 in nasal NK cell lymphoma.......31 中文摘要…………………………………………………………32 Abstract…………………………………………………………33 Introduction……………………………………………………37 Materials and Methods…………………………………………39 Results…………………………………….………………………46 Discussion…………………………………………………………50 References…………………………………………………………54 Table……………………………………….....…………………59 Figure………………………………………………………………61 | |
| dc.language.iso | en | |
| dc.subject | 黏膜內層 | zh_TW |
| dc.subject | 轉錄因子ETS-1 | zh_TW |
| dc.subject | 轉錄因子T-bet | zh_TW |
| dc.subject | NK/T細胞淋巴癌 | zh_TW |
| dc.subject | ETS-1 | en |
| dc.subject | intramucosal | en |
| dc.subject | nasal NK/T-cell lymphoma | en |
| dc.subject | T-bet | en |
| dc.title | EBV微RNA-BART20-5p在NK細胞淋巴癌中直接抑制T-bet並間接抑制p53 | zh_TW |
| dc.title | EBV-encoded miR-BART20-5p inhibits T-bet with secondary suppression of p53 in NK-cell lymphoma | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 101-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 張逸良,郭頌鑫,黃聖懿 | |
| dc.subject.keyword | 轉錄因子ETS-1,轉錄因子T-bet,NK/T細胞淋巴癌,黏膜內層, | zh_TW |
| dc.subject.keyword | ETS-1,T-bet,nasal NK/T-cell lymphoma,intramucosal, | en |
| dc.relation.page | 68 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2012-12-24 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 病理學研究所 | zh_TW |
| 顯示於系所單位： | 病理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-101-1.pdf 未授權公開取用 | 2.09 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。